Eko Appoints Bryan Humbarger to the Position of Senior Vice President, Commercial

Bryan Humbarger has been appointed to the position of Senior Vice President, Eko Commercial. In this role, Mr. Humbarger will oversee sales and commercial operations for Eko’s AI and telemedicine software platforms for health systems, practices and providers worldwide.

Mr. Humbarger most recently served as Vice President of Sales at cardiac digital health companies AliveCor and Heartflow. Previously, he spent nearly two decades gaining sales experience at medical device and technology companies, including Medtronic and Bioquell.

“Bryan’s leadership skills, proven ability to drive growth and passion for improving cardiac health will be key assets as Eko continues to expand adoption of our AI and telemedicine solutions,” said Connor Landgraf, CEO and co-founder of Eko. “Now more than ever, telemedicine is playing a critical role in caring for patients and Bryan will play a pivotal part in scaling operations for the company’s next phase of growth and continued expansion.”

Mr. Humbarger joins Eko following the achievement of several key company milestones, including the clearance of its cardiac AI algorithms by the U.S. Food and Drug Administration and the launch of Eko’s AI-powered telehealth platform.

“Eko’s next generation of cardiac and pulmonary solutions are already making a difference for providers and their patients, and I am thrilled to bring my experience in cardiology and digital health to further accelerate the adoption of Eko’s technology,” said Mr. Humbarger. “Being at the forefront of delivering what’s next in cardiovascular care is my passion, and I am thrilled to continue this journey at Eko, a company making a difference in how cardiac and pulmonary care is delivered.”

Subscribe to Medical Device News Magazine

SourceEko

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version